JP2013023487A - 抗糖化作用剤 - Google Patents
抗糖化作用剤 Download PDFInfo
- Publication number
- JP2013023487A JP2013023487A JP2011161524A JP2011161524A JP2013023487A JP 2013023487 A JP2013023487 A JP 2013023487A JP 2011161524 A JP2011161524 A JP 2011161524A JP 2011161524 A JP2011161524 A JP 2011161524A JP 2013023487 A JP2013023487 A JP 2013023487A
- Authority
- JP
- Japan
- Prior art keywords
- glycation
- extract
- acteoside
- ages
- action
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000284 extract Substances 0.000 claims abstract description 49
- 229930185474 acteoside Natural products 0.000 claims abstract description 38
- FBSKJMQYURKNSU-ZLSOWSIRSA-N acteoside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC(=O)\C=C\C=2C=C(O)C(O)=CC=2)[C@@H](CO)O[C@@H](OCCC=2C=C(O)C(O)=CC=2)[C@@H]1O FBSKJMQYURKNSU-ZLSOWSIRSA-N 0.000 claims abstract description 37
- FBSKJMQYURKNSU-UKQWSTALSA-N acteoside I Natural products C[C@@H]1O[C@H](O[C@@H]2[C@@H](O)[C@H](OCCc3ccc(O)c(O)c3)O[C@H](CO)[C@H]2OC(=O)C=Cc4ccc(O)c(O)c4)[C@H](O)[C@H](O)[C@H]1O FBSKJMQYURKNSU-UKQWSTALSA-N 0.000 claims abstract description 37
- QFRYQWYZSQDFOS-UHFFFAOYSA-N verbascoside Natural products CC1OC(COC2C(O)C(COC3OC(C(O)C(O)C3O)C(=O)O)OC(Oc4cc(O)cc5OC(=CC(=O)c45)c6ccc(O)c(O)c6)C2O)C(O)C(O)C1O QFRYQWYZSQDFOS-UHFFFAOYSA-N 0.000 claims abstract description 37
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 18
- 239000004480 active ingredient Substances 0.000 claims abstract description 17
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 12
- 230000009471 action Effects 0.000 claims description 24
- 230000036252 glycation Effects 0.000 claims description 19
- 230000015556 catabolic process Effects 0.000 claims description 13
- 238000006731 degradation reaction Methods 0.000 claims description 13
- 230000001737 promoting effect Effects 0.000 claims description 9
- 235000004789 Rosa xanthina Nutrition 0.000 claims 1
- 241000220222 Rosaceae Species 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 abstract description 27
- 230000000694 effects Effects 0.000 abstract description 9
- 238000000354 decomposition reaction Methods 0.000 abstract description 7
- 239000000126 substance Substances 0.000 abstract description 7
- 244000242564 Osmanthus fragrans Species 0.000 abstract description 4
- 235000019083 Osmanthus fragrans Nutrition 0.000 abstract description 4
- 229930014626 natural product Natural products 0.000 abstract description 3
- 108010005094 Advanced Glycation End Products Proteins 0.000 abstract 3
- 238000000605 extraction Methods 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- 238000006243 chemical reaction Methods 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 16
- 108090000623 proteins and genes Proteins 0.000 description 16
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 15
- 235000017803 cinnamon Nutrition 0.000 description 15
- 239000002904 solvent Substances 0.000 description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 11
- 239000000523 sample Substances 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 239000000872 buffer Substances 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 239000002994 raw material Substances 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 230000002265 prevention Effects 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical group ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 206010003210 Arteriosclerosis Diseases 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 208000001132 Osteoporosis Diseases 0.000 description 5
- 241000218201 Ranunculaceae Species 0.000 description 5
- 208000011775 arteriosclerosis disease Diseases 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000011259 mixed solution Substances 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 208000002249 Diabetes Complications Diseases 0.000 description 4
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 4
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 4
- 206010012655 Diabetic complications Diseases 0.000 description 4
- 206010012689 Diabetic retinopathy Diseases 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 208000033679 diabetic kidney disease Diseases 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 201000008482 osteoarthritis Diseases 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000012264 purified product Substances 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 230000037394 skin elasticity Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 241001417534 Lutjanidae Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- PYMYPHUHKUWMLA-LMVFSUKVSA-N aldehydo-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 3
- -1 aliphatic alcohols Chemical class 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000002798 polar solvent Substances 0.000 description 3
- 150000005846 sugar alcohols Polymers 0.000 description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 241000254173 Coleoptera Species 0.000 description 2
- 102000012422 Collagen Type I Human genes 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 241001573881 Corolla Species 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000218206 Ranunculus Species 0.000 description 2
- 241000592344 Spermatophyta Species 0.000 description 2
- 239000012752 auxiliary agent Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000005238 degreasing Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000014639 sexual reproduction Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 240000006891 Artemisia vulgaris Species 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000579185 Bucerotidae Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000723438 Cercidiphyllum japonicum Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000723347 Cinnamomum Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000218691 Cupressaceae Species 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004129 EU approved improving agent Substances 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 239000002262 Schiff base Substances 0.000 description 1
- 150000004753 Schiff bases Chemical class 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- QQFYLZXBFWWJHR-UHFFFAOYSA-M benzyl(triethyl)phosphanium;bromide Chemical compound [Br-].CC[P+](CC)(CC)CC1=CC=CC=C1 QQFYLZXBFWWJHR-UHFFFAOYSA-M 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229910052956 cinnabar Inorganic materials 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 108091005996 glycated proteins Proteins 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000002349 well water Substances 0.000 description 1
- 235000020681 well water Nutrition 0.000 description 1
- 238000004383 yellowing Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
【解決手段】本発明の抗糖化作用剤の有効成分として、キンモクセイからの抽出物及び/又はアクテオシド(Acteoside)を含有させる。キンモクセイからの抽出物及び/又は前記アクテオシド(Acteoside)は、最終糖化生成物(AGEs)の形成抑制作用及び/又は分解促進作用を有することが好ましい。
【選択図】なし
Description
本実施形態の抗糖化作用剤は、キンモクセイからの抽出物及び/又はアクテオシド(Acteoside)を有効成分として含有するものである。
キンモクセイの花部の粗粉砕物150gに50質量%エタノール(水とエタノールとの質量比=1:1)1500mLを加え、穏やかに攪拌しながら80℃にて2時間保ち、熱時濾過した。続いて、残渣に50質量%エタノール1500mLを加え、穏やかに攪拌しながら80℃にて2時間保ち、熱時濾過した。得られた濾液を合わせて減圧下にて濃縮し、減圧乾燥機で乾燥してキンモクセイ花部抽出物(71.4g,試料1)を得た。
製造例1により得られたキンモクセイ花部抽出物(試料1)8.9gをクロロホルム/メタノール/水=10:5:1の混合溶液に溶解し、シリカゲル(商品名:シリカゲル60,メルク社製)を充填したガラス製のカラム上部より流入して、シリカゲルに吸着させた。ガラス製のカラムに移動層としてクロロホルム/メタノール/水=10:5:1を流し、その溶出液を集め、溶媒を留去して、精製物(2.5g,試料2)を得た。
[M−H]− m/z 623(理論値:C29H36O15−H=623)
[M+Na]+ m/z 647(理論値:C29H36O15+Na=647)
6.69 (1H, d, J=2.0 Hz, H-2), 6.67 (1H, d, J=8.1 Hz, H-5), 6.55 (1H, dd, J=2.0, 8.1Hz, H-6), 2.78 (2H, t-like, H-7), 4.01 (1H, overlapped, H-8a), 3.70 (1H, overlapped, H-8b), 7.05 (1H, d, J=2.2 Hz, H-2’), 6.77 (1H, d, J=8.3 Hz, H-5’), 6.94 (1H, dd, J=2.2, 8.3Hz, H-6’), 7.58 (1H, d, J=15.9 Hz, H-7’), 6.27 (1H, d, J=15.9 Hz, H-8’), 4.36 (1H, d, J=7.8Hz, GlcH-1), 3.39 (1H, dd, J=7.8, 8.1Hz, GlcH-2), 3.80(1H, br.t, J=9.0 Hz, Glc H-3), 4.88 (1H, br.t, J=9.2 Hz, Glc H-4), 3.58 (1H, overlapped, Glc H-5), 3.48 (2H, overlapped, Glc H-6), 5.18( 1H, br.s, Rha H-1), 3.90 (1H, m, Rha H-2), 3.58 (2H, overlapped, Rha-H-3 and Rha H-5), 3.30(1H, overlapped, Rha-H-4), 1.08.(3H, d, J=6.1 Hz, Rha H-6)
131.1(s, C-1), 116.1(d, C-2), 146.5(s, C-3), 144.3(s, C-4), 116.8(d, C-5), 121.0(d, C-6), 36.4(t, C-7), 72.0(t, C-8), 127.3(s, C-1’), 114.9(d, C-2’), 145.8(s, C-3’), 149.4(s, C-4’), 116.2(d, C-5’), 122.9(d, C-6’), 147.7(d, C-7’), 114.4(d, C-8’), 167.9(s, C-9’), 103.9(d, Glc C-1), 75.9(d, Glc C-2), 81.4(d, Glc C-3), 70.7(d, Glc C-4), 75.8(d, Glc C-5), 62.1(t, Glc C-6), 102.7(d, Rha C-1), 72.1(d, Rha C-2), 71.8(d, Rha C-3), 73.5(d, Rha C-4), 70.2(d, RhaC-5), 18.3(q, Rha C-6)
製造例1及び2により得られたキンモクセイ花部抽出物(試料1)、及びアクテオシド(試料2)について、以下のようにして最終糖化生成物(AGEs)の形成抑制作用を試験した。
式中、Aは「陰性対照の波長405nmにおける吸光度」を表し、Bは「陽性対照の波長405nmにおける吸光度」を表し、Cは「被験試料添加時の波長405nmにおける吸光度」を表す。
結果を表1に示す。
製造例1及び2により得られたキンモクセイ花部抽出物(試料1)、及びアクテオシド(試料2)について、以下のようにして最終糖化生成物(AGEs)の分解促進作用を試験した。
式中、Aは「陰性対照の波長405nmにおける吸光度」を表し、Bは「陽性対照の波長405nmにおける吸光度」を表し、Cは「被験試料添加時の波長405nmにおける吸光度」を表す。
結果を表2に示す。
Claims (3)
- キンモクセイからの抽出物を有効成分として含有することを特徴とする抗糖化作用剤。
- アクテオシド(Acteoside)を有効成分として含有することを特徴とする抗糖化作用剤。
- 前記キンモクセイからの抽出物又は前記アクテオシド(Acteoside)が、最終糖化生成物(AGEs)の形成抑制作用及び/又は分解促進作用を有することを特徴とする請求項1又は2に記載の抗糖化作用剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011161524A JP5969738B2 (ja) | 2011-07-25 | 2011-07-25 | 抗糖化作用剤 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011161524A JP5969738B2 (ja) | 2011-07-25 | 2011-07-25 | 抗糖化作用剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013023487A true JP2013023487A (ja) | 2013-02-04 |
JP5969738B2 JP5969738B2 (ja) | 2016-08-17 |
Family
ID=47782219
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011161524A Active JP5969738B2 (ja) | 2011-07-25 | 2011-07-25 | 抗糖化作用剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP5969738B2 (ja) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103768152A (zh) * | 2014-01-29 | 2014-05-07 | 浙江大学 | 桂花苯乙醇苷提取物及其制备方法和用途 |
CN103767975A (zh) * | 2014-01-29 | 2014-05-07 | 浙江大学 | 桂花苯乙醇苷提取物在制备美白化妆品中的应用 |
CN103768151A (zh) * | 2014-01-29 | 2014-05-07 | 浙江大学 | 桂花苯乙醇苷提取物在制备抗衰老药物或保健品中的应用 |
CN104231011A (zh) * | 2014-09-12 | 2014-12-24 | 苏州禾研生物技术有限公司 | 一种毛蕊花糖苷的制备方法 |
JP2015168656A (ja) * | 2014-03-07 | 2015-09-28 | 丸善製薬株式会社 | Tie2活性化剤、血管新生抑制剤、血管の成熟化剤、血管の正常化剤、及び血管の安定化剤、並びに医薬品組成物 |
EP2861208A4 (en) * | 2012-05-14 | 2015-12-23 | Biocogent Llc | PREVENTING FAILURE OF FIBROBLASTS |
WO2016000663A1 (zh) * | 2014-07-03 | 2016-01-07 | 杏辉天力(杭州)药业有限公司 | 管花肉苁蓉萃取物在制备保护眼部细胞的药物或食品中的用途 |
JP2016006036A (ja) * | 2014-05-26 | 2016-01-14 | アークレイ株式会社 | AGEs分解剤およびその用途 |
CN108451961A (zh) * | 2018-06-15 | 2018-08-28 | 南京中医药大学 | 毛蕊花糖苷在治疗和预防ii型糖尿病肾病中的应用 |
CN108727471A (zh) * | 2018-06-06 | 2018-11-02 | 南京医科大学 | 一种脂肪组织靶向性多肽-毛蕊花苷-纳米金颗粒衍生物及其制备方法和应用 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107375308B (zh) | 2017-09-04 | 2021-02-12 | 四川美大康药业股份有限公司 | 毛蕊花糖苷在制备预防或治疗肾小球足细胞损伤型肾脏疾病的药物中的用途 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0236189A (ja) * | 1988-07-26 | 1990-02-06 | Tsumura & Co | 新規フエネチルアルコール誘導体およびフエネチルアルコール誘導体を有効成分とするアルドースリダクターゼ阻害剤 |
JP2005126368A (ja) * | 2003-10-23 | 2005-05-19 | Pias Arise Kk | 皮膚外用剤 |
JP2009067749A (ja) * | 2007-09-14 | 2009-04-02 | Maruzen Pharmaceut Co Ltd | マトリックスメタロプロテアーゼ−1(mmp−1)阻害剤、マトリックスメタロプロテアーゼ−2(mmp−2)阻害剤、エストロゲン様作用剤、プロフィラグリン産生促進剤、フィラグリン産生促進剤、抗肥満剤及びサイクリックampホスホジエステラーゼ活性阻害剤 |
-
2011
- 2011-07-25 JP JP2011161524A patent/JP5969738B2/ja active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0236189A (ja) * | 1988-07-26 | 1990-02-06 | Tsumura & Co | 新規フエネチルアルコール誘導体およびフエネチルアルコール誘導体を有効成分とするアルドースリダクターゼ阻害剤 |
JP2005126368A (ja) * | 2003-10-23 | 2005-05-19 | Pias Arise Kk | 皮膚外用剤 |
JP2009067749A (ja) * | 2007-09-14 | 2009-04-02 | Maruzen Pharmaceut Co Ltd | マトリックスメタロプロテアーゼ−1(mmp−1)阻害剤、マトリックスメタロプロテアーゼ−2(mmp−2)阻害剤、エストロゲン様作用剤、プロフィラグリン産生促進剤、フィラグリン産生促進剤、抗肥満剤及びサイクリックampホスホジエステラーゼ活性阻害剤 |
Non-Patent Citations (2)
Title |
---|
PHYTOCHEMISTRY, vol. 14, no. 9, JPN6012049652, 1975, pages 2029 - 2032, ISSN: 0003229235 * |
第43回日本結合組織学会学術大会・第58回マトリックス研究会大会合同学術集会 プログラム・抄録集, JPN6015019638, 18 May 2011 (2011-05-18), pages 111, ISSN: 0003352525 * |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2861208A4 (en) * | 2012-05-14 | 2015-12-23 | Biocogent Llc | PREVENTING FAILURE OF FIBROBLASTS |
CN103767975A (zh) * | 2014-01-29 | 2014-05-07 | 浙江大学 | 桂花苯乙醇苷提取物在制备美白化妆品中的应用 |
CN103768151A (zh) * | 2014-01-29 | 2014-05-07 | 浙江大学 | 桂花苯乙醇苷提取物在制备抗衰老药物或保健品中的应用 |
CN103768152A (zh) * | 2014-01-29 | 2014-05-07 | 浙江大学 | 桂花苯乙醇苷提取物及其制备方法和用途 |
JP2015168656A (ja) * | 2014-03-07 | 2015-09-28 | 丸善製薬株式会社 | Tie2活性化剤、血管新生抑制剤、血管の成熟化剤、血管の正常化剤、及び血管の安定化剤、並びに医薬品組成物 |
JP2016006036A (ja) * | 2014-05-26 | 2016-01-14 | アークレイ株式会社 | AGEs分解剤およびその用途 |
RU2688939C2 (ru) * | 2014-07-03 | 2019-05-23 | СИНЬФАР ТЯНЬ-ЛИ ФАРМАСЬЮТИКАЛ Ко., ЭлТэДэ. (ХАНЧЖОУ) | Применение экстракта cistanche tubulosa в получении лекарственных средств или продуктов питания для защиты клеток глаза |
WO2016000663A1 (zh) * | 2014-07-03 | 2016-01-07 | 杏辉天力(杭州)药业有限公司 | 管花肉苁蓉萃取物在制备保护眼部细胞的药物或食品中的用途 |
US10967029B2 (en) | 2014-07-03 | 2021-04-06 | Sinphar Pharmaceutical Co., Ltd. | Method of using Cistanche tubulosa extract to prevent, slow down, or treat an eye disease caused by oxidative stress |
CN104231011A (zh) * | 2014-09-12 | 2014-12-24 | 苏州禾研生物技术有限公司 | 一种毛蕊花糖苷的制备方法 |
CN108727471A (zh) * | 2018-06-06 | 2018-11-02 | 南京医科大学 | 一种脂肪组织靶向性多肽-毛蕊花苷-纳米金颗粒衍生物及其制备方法和应用 |
CN108727471B (zh) * | 2018-06-06 | 2021-08-27 | 南京医科大学 | 一种脂肪组织靶向性多肽-毛蕊花苷-纳米金颗粒衍生物及其制备方法和应用 |
CN108451961A (zh) * | 2018-06-15 | 2018-08-28 | 南京中医药大学 | 毛蕊花糖苷在治疗和预防ii型糖尿病肾病中的应用 |
Also Published As
Publication number | Publication date |
---|---|
JP5969738B2 (ja) | 2016-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5969738B2 (ja) | 抗糖化作用剤 | |
JP5230152B2 (ja) | プロフィラグリン産生促進剤及びフィラグリン産生促進剤 | |
JP5860579B2 (ja) | フィラグリン産生促進剤、インボルクリン産生促進剤、及びトランスグルタミナーゼ−1産生促進剤 | |
JP5719581B2 (ja) | 抗糖化作用剤 | |
WO2022215441A1 (ja) | 新規ポリフェノール化合物 | |
JP6781549B2 (ja) | Endo180産生促進剤 | |
JP5751981B2 (ja) | 新規フェニルエタノイド配糖体及び皮膚化粧料 | |
JP2007045755A (ja) | 美白剤、抗アレルギー剤及び食料品 | |
JP2014221739A (ja) | Vii型コラーゲン発現促進剤 | |
WO2022254867A1 (ja) | 新規フェニルプロパノイド化合物 | |
JP6923100B1 (ja) | 新規イソフラボン化合物 | |
JP2012041276A (ja) | タンパク質のカルボニル化抑制剤及び肌の透明感向上剤 | |
JP6723979B2 (ja) | しわ改善剤 | |
JP6175216B2 (ja) | 関節炎の予防・治療剤 | |
JP5992661B2 (ja) | ヒアルロン酸産生促進剤 | |
JP2010065007A (ja) | クローディン−1産生促進剤及び皮膚バリア機能改善剤 | |
JP2009114146A (ja) | トランスグルタミナーゼ−1産生促進剤及びインボルクリン産生促進剤 | |
JP6807425B2 (ja) | Endo180産生促進剤 | |
JP5132030B2 (ja) | 免疫賦活剤、抗腫瘍剤、抗炎症剤、抗老化剤及び皮膚化粧料 | |
JP5946698B2 (ja) | 美白剤及び皮膚化粧料 | |
JP2019182753A (ja) | Endo180産生促進剤 | |
JP2024001415A (ja) | プロスタグランジンe2産生抑制剤及び抗炎症剤 | |
JP7455350B2 (ja) | 大気汚染物質によるダメージ抑制剤、化粧料及び飲食品 | |
JP7402478B2 (ja) | 神経成長因子発現抑制剤およびセマフォリン3a発現促進剤 | |
JP2023102984A (ja) | Endo180産生促進剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140528 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150526 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150727 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160112 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20160308 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160311 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160705 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160708 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5969738 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |